LogicBio Therapeutics reaches 52-week high amid market discussion
1 report, 1 independent
Updated Sep 23
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
LogicBio Therapeutics reached a new 52-week high during mid-day trading on September 23, 2026. The stock traded as high as $15.25, closing at $15.1850 on a volume of 29,037 shares. The company, which is a clinical-stage genetic medicine company, reported quarterly earnings of ($0.14) earnings per share for the period ending August 13th, missing the consensus estimate of ($0.04) by ($0.10).
From themarketsdaily.com
Why it matters
The stock movement reflects investor sentiment regarding the company's clinical-stage business model and recent financial performance. LogicBio Therapeutics focuses on technologies like GeneRide and GeneWare for rare and serious genetic diseases.
From themarketsdaily.com
Who's involved
- CambridgeClinical-stage genetic medicine company based in Cambridge, Massachusetts